



COVID-19 IMMUNITY
TASK FORCE

Spotlight on CITF-FUNDED RESEARCH



CITF-Funded Research Results

SARS-CoV-2 monovalent mRNA vaccines are safe for those with inflammatory bowel disease

A CITF-funded study, published in *The American Journal of Gastroenterology*, found that SARS-CoV-2 vaccines are safe for those with inflammatory bowel disease (IBD). Injection site reactions were the most common adverse event, most common after earlier doses, but when following a 4th dose, they were significantly associated with increased antibody levels.

[Read more](#)

STOPCoV participants reported high satisfaction with digital research platform

The digital research platform used by a CITF-funded study, Safety and Efficacy of Preventative COVID Vaccines (STOPCoV), was easy to use and popular, including among those aged 70+. Although only 33% of participants (ranging in age from 30 to above 70 years) had previously participated in clinical research, 95% were very satisfied with their participation and 90% indicated that they would participate in research again. The results were published in *PLOS Digital Health*.

[Read more](#)

Most CanPath study participants had infection-acquired antibodies but few suspected COVID-19

Of the 62% of participants in a CanPath study who had infection-acquired antibodies, 86% had never suspected they had previously had COVID-19. These results of the CanPath SUPPORT-Canada study “Real-world insights on COVID-19 vaccine effectiveness and risk factors for COVID-19 infection” were made public during a hybrid event on May 30th.

[Read more](#)



Share!

Know policymakers or researchers who may be interested in our latest research results? Please share this email and encourage them to subscribe!

[Sign Up](#)

Have a publication we should review or know about? Please share with us at research@covid19immunitytaskforce.ca

Missed an issue of Spotlight on CITF-Funded Research? [View back issues.](#)

The views expressed herein do not necessarily represent the views of the
Public Health Agency of Canada.